1. Effect of hyperthermia and proton beam radiation as a novel approach in chordoma cells death and its clinical implication to treat chordoma
- Author
-
Zeljko Vujaskovic, Binny Bhandary, Dario B. Rodrigues, Sina Mossahebi, John Eley, Hem D. Shukla, Minjie Chen, Nayab Mahmood, Tijana Dukic, Javed Mahmood, Prerna Singh, and Ali Saeed
- Subjects
Hyperthermia ,Radiation-Sensitizing Agents ,Brachyury ,Programmed cell death ,Radiosensitizer ,Radiological and Ultrasound Technology ,business.industry ,Apoptosis ,Hyperthermia, Induced ,Receptors, Death Domain ,medicine.disease ,Cell killing ,Chordoma ,Proton Therapy ,Cancer research ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Protons ,business ,Sacral Chordoma - Abstract
PURPOSE Chordoma is a locally aggressive tumor that most commonly affects the base of the skull/clivus, cervical, and sacral spine. Conventional radiotherapy (RT), cannot be safely increased further to improve disease control due to the risk of toxicity to the surrounding critical structures. Tumor-targeted hyperthermia (HT) combined with Proton Beam Radiation Therapy (PBRT) is known to act as a potent radiosensitizer in cancer control. In this study, we investigated whether PBRT efficacy for chordoma can be enhanced in combination with HT as a radiosensitizer. MATERIAL AND METHODS Human chordoma cell lines, U-CH2 and Mug-chor1 were treated in vitro with HT followed by PBRT with variable doses. The colony-forming assay was performed, and dose-response was characterized by linear-quadratic model fits. HSP-70 and Brachyury (TBXT) biomarkers for chordoma aggression levels were quantified by western blot analysis. Gene microarray analysis was performed by U133 Arrays. Pathway Analysis was also performed using IPA bioinformatic software. RESULTS Our findings in both U-CH2 and Mug-Chor1 cell lines demonstrate that hyperthermia followed by PBRT has an enhanced cell killing effect when compared with PBRT-alone (p
- Published
- 2021